[{"orgOrder":0,"company":"Longhorn Vaccines & Diagnostics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"AddaVax","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Longhorn Vaccines & Diagnostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Longhorn Vaccines & Diagnostics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Longhorn Vaccines & Diagnostics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Longhorn Vaccines & Diagnostics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Coronavirus Pep02 Composite Peptide Vaccines comprised of Coronavirus (SARS-CoV-2 RNA Polymerase) and Influenza epitopes (Tetanus T cell epitope) Generated Antisera Reponses to Both Coronavirus and Influenza.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          October 19, 2022

                          Lead Product(s) : Coronavirus Pep02,AddaVax

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank